Aspen Aerogels, Inc.
ASPNBasic MaterialsNASDAQSpecialty Chemicals
Scan Results
Daily timeframePart of the basic materials sector, Aspen Aerogels, Inc. (ASPN) is listed under Specialty Chemicals. With a market capitalization of $458.1M, it sits in small-cap territory. It operates through two segments: Thermal Barrier and Energy Industrial.
Market Cap
$458.1M
Beta
3.06
P/E (TTM)
—
P/E (Fwd)
-35.61
EPS (TTM)
$-1.48
EPS (Fwd)
$-0.15
ROE
-50.4%
ROA
-8.5%
Cash
$151.7M
Total Debt
$125.1M
Free CF
$44.1M
52W Change
-32.1%
Annual Financials
Cash vs Debt
Where ASPN stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, ASPN finished 4.64% above its 150-day moving average ($4.96) and 13.57% above its 200-day moving average ($4.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ASPN overbought or oversold?
At the October 19, 2026 close, ASPN's RSI(14) was 50.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $151.7M in cash and $125.1M in debt, ASPN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $44.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -50.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $180.4M (2022) to $271.1M (2025), reflecting a 50% increase over the period.
With a beta above 1.5, ASPN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ASPN.